loading
Precedente Chiudi:
$7.64
Aprire:
$7.6
Volume 24 ore:
319.89K
Relative Volume:
0.75
Capitalizzazione di mercato:
$529.95M
Reddito:
-
Utile/perdita netta:
$-153.16M
Rapporto P/E:
-2.103
EPS:
-3.69
Flusso di cassa netto:
$-134.48M
1 W Prestazione:
-2.02%
1M Prestazione:
-11.31%
6M Prestazione:
-37.37%
1 anno Prestazione:
-52.42%
Intervallo 1D:
Value
$7.525
$8.05
Intervallo di 1 settimana:
Value
$7.255
$8.05
Portata 52W:
Value
$6.85
$21.01

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name
Nome
Cullinan Therapeutics Inc
Name
Telefono
617-410-4650
Name
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Name
Dipendente
111
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
CGEM's Discussions on Twitter

Confronta CGEM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CGEM
Cullinan Therapeutics Inc
7.76 529.95M 0 -153.16M -134.48M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-11 Ripresa Stifel Buy
2024-10-24 Iniziato UBS Buy
2024-05-01 Iniziato Stifel Buy
2024-04-15 Iniziato William Blair Outperform
2024-02-15 Iniziato Wedbush Outperform
2023-06-15 Iniziato TD Cowen Outperform
2022-11-21 Iniziato BTIG Research Buy
2021-04-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-02-02 Iniziato Evercore ISI Outperform
2021-02-02 Iniziato Morgan Stanley Equal-Weight
2021-02-02 Iniziato SVB Leerink Outperform
2021-02-01 Iniziato H.C. Wainwright Buy
Mostra tutto

Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie

pulisher
Jun 17, 2025

Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World

Jun 17, 2025
pulisher
Jun 12, 2025

Cullinan Management Holds Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech

Jun 12, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India

Jun 05, 2025
pulisher
Jun 04, 2025

Transcript : Cullinan Therapeutics, Inc.Special Call - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan expands autoimmune focus with new T cell engager license - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics (CGEM) Secures Exclusive License for Velinotamig Development | CGEM Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Management Enters Global License Agreement with Genrix - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan in pact for multiple myeloma drug (CGEM:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune

Jun 04, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILI - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - MarketScreener

Jun 01, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire

Jun 01, 2025
pulisher
Jun 01, 2025

ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - Yahoo Finance

May 29, 2025
pulisher
May 26, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025
pulisher
May 24, 2025

Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 24, 2025
pulisher
May 22, 2025

Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 21, 2025
pulisher
May 20, 2025

115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World

May 20, 2025
pulisher
May 15, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World

May 15, 2025
pulisher
May 14, 2025

Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Cullinan Therapeutics Inc Azioni (CGEM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
AHMED NADIM
President and CEO
Feb 25 '25
Sale
8.53
12,529
106,872
430,621
Michaelson Jennifer
Chief Scientific Officer
Feb 25 '25
Sale
8.53
3,756
32,039
142,004
SUMER JACQUELYN L
Chief Legal Officer
Feb 25 '25
Sale
8.53
3,756
32,039
136,895
Michaelson Jennifer
Chief Scientific Officer
Jan 06 '25
Sale
12.51
4,000
50,040
95,760
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):